944457-66-3

Basic information

• Product Name: octanedioic acid {2'-[2-amino-3-(4-benzyloxyphenyl)propionylamino]biphenyl-4-yl}amide benzyloxyamide
• Synonyms: octanedioic acid {2'-[2-amino-3-(4-benzyloxyphenyl)propionylamino]biphenyl-4-yl}amide benzyloxyamide
• CAS NO: 944457-66-3
• Molecular Weight: 698.862
• Mol File: 944457-66-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: octanedioic acid {2'-[2-amino-3-(4-benzyloxyphenyl)propionylamino]biphenyl-4-yl}amide benzyloxyamide(CAS DataBase Reference)
• NIST Chemistry Reference: octanedioic acid {2'-[2-amino-3-(4-benzyloxyphenyl)propionylamino]biphenyl-4-yl}amide benzyloxyamide(944457-66-3)
• EPA Substance Registry System: octanedioic acid {2'-[2-amino-3-(4-benzyloxyphenyl)propionylamino]biphenyl-4-yl}amide benzyloxyamide(944457-66-3)

Safety Data

• Hazardous Substances Data: 944457-66-3(Hazardous Substances Data)

Upstream product

• 6272-52-2 2-(4-nitrophenyl)aniline 
• 2130-96-3 O-benzyl-N-tert-butoxycarbonyl-L-tyrosine 
• 944457-74-3 [1-(4'-amino-biphenyl-2-ylcarbamoyl)-2-(4-benzyloxyphenyl)ethyl]carbamic acid tert-butyl ester 
• 944457-73-2 C₃₃H₃₃N₃O₆ 
• 944457-75-4 [1-[4'-(7-benzyloxycarbamoyl-heptanoylamino)biphenyl-2-ylcarbamoyl]-2-(4-benzyloxy-phenyl)ethyl]carbamic acid tert-butyl ester 

Relevant articles and documents

Functional differences in epigenetic modulators - Superiority of mercaptoacetamide-based histone deacetylase inhibitors relative to hydroxamates in cortical neuron neuroprotection studies

We compare the ability of two structurally different classes of epigenetic modulators, namely, histone deacetylase (HDAC) inhibitors containing either a hydroxamate or a mercaptoacetamide as the zinc binding group, to protect cortical neurons in culture from oxidative stress-induced death. This study reveals that some of the mercaptoacetamide-based HDAC inhibitors are fully protective, whereas the hydroxamates show toxicity at higher concentrations. Our present results appear to be consistent with the possibility that the mercaptoacetamide-based HDAC inhibitors interact with a different subset of the HDAC isozymes [less activity at HDAC1 and 2 correlates with less inhibitor toxicity], or alternatively, are interacting selectively with only the cytoplasmic HDACs that are crucial for protection from oxidative stress.